CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-22 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,400 | $45.00 | $63K | 225,078 |
| 2018-02-21 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,589 | $43.60 | $69K | 232,589 |
| 2018-02-21 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,911 | $44.55 | $130K | 229,678 |
| 2018-02-20 | Ciechanover Isaac E. Chief Executive Officer | Sale | −8,700 | $45.28 | $394K | 234,178 |
| 2018-02-16 | Gallagher Carol Giltner Director | Sale | −1,183 | $46.50 | $55K | 110,920 |
| 2018-02-16 | MCGRATH JOHN EVP & Chief Financial Officer | Sale | −4,000 | $46.93 | $188K | 97,262 |
| 2018-02-16 | MCGRATH JOHN EVP & Chief Financial Officer | Sale | −2,500 | $48.08 | $120K | 94,762 |
| 2018-02-16 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,000 | $45.44 | $136K | 249,878 |
| 2018-02-16 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,600 | $46.55 | $74K | 248,278 |
| 2018-02-16 | Ciechanover Isaac E. Chief Executive Officer | Sale | −5,100 | $47.91 | $244K | 243,178 |
| 2018-02-16 | Ciechanover Isaac E. Chief Executive Officer | Sale | −300 | $48.43 | $15K | 242,878 |
| 2018-02-15 | Gallagher Carol Giltner Director | Option exercise | +1,548 | 111,286 | ||
| 2018-02-15 | Gallagher Carol Giltner Director | Option exercise | +817 | 112,103 | ||
| 2018-02-15 | Gallagher Carol Giltner Director | Option exercise · Restricted Stock Units | −1,548 | 0 | ||
| 2018-02-15 | Gallagher Carol Giltner Director | Option exercise · Restricted Stock Units | −817 | 545 | ||
| 2018-02-15 | Fust Matthew K Director | Option exercise | +1,603 | 32,106 | ||
| 2018-02-15 | Fust Matthew K Director | Option exercise · Restricted Stock Units | −1,603 | 534 | ||
| 2018-02-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise | +553 | 351,232 | ||
| 2018-02-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise · Restricted Stock Units | −553 | 0 | ||
| 2018-02-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise | +7,211 | 187,124 |
Page 34 of 44 · 867 trades